Summary
Asciminib has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Non-Hodgkin Lymphoma (NHL) would be drug repurposing rather than first-in-human development. This does not mean it is approved for Non-Hodgkin Lymphoma (NHL). ClinicalTrials.gov lists 1 registered trial linking Asciminib to Non-Hodgkin Lymphoma (NHL): 1 is currently recruiting. The most advanced is Phase 1 (NCT03595917). It plans or enrolled 40 participants. Registered activity dates to 2018. No published literature item is linked to Asciminib and Non-Hodgkin Lymphoma (NHL) in the OSMF database yet, so the record rests on registry entries alone. Registry entries describe intent to study, not outcomes.
The RepurpOS disease-intelligence file for Non-Hodgkin Lymphoma ranks 50 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Indolent NHL (follicular): spontaneous remission in 20-30% of early-stage, allowing watch-and-wait; aggressive NHL (DLBCL): rapidly lethal without treatment in weeks-months.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 23.5 (trials 3.5, literature 0.0, tier 15, approved bonus 5.0) |
| Registered trials | 1 total: 1 recruiting, 0 active / not yet recruiting, 0 completed, 0 other |
| Linked publications | 0 |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | modulator; inhibitor |
| Data sources | DGIdb |
| Linked via biomarker / target | BCR |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT03595917 | ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML 2018 | recruiting | Phase 1 | 40 |
Published literature
No publication is linked to this pair yet.
Mechanism and notes
Recorded mechanism or class: modulator; inhibitor.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target BCR. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Asciminib approved for Non-Hodgkin Lymphoma (NHL)?
Asciminib has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Non-Hodgkin Lymphoma (NHL) would be drug repurposing rather than first-in-human development. This does not mean it is approved for Non-Hodgkin Lymphoma (NHL). Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Asciminib in clinical trials for Non-Hodgkin Lymphoma (NHL)?
ClinicalTrials.gov lists 1 registered trial linking Asciminib to Non-Hodgkin Lymphoma (NHL): 1 is currently recruiting. The most advanced is Phase 1 (NCT03595917). It plans or enrolled 40 participants. Registered activity dates to 2018.
What does the evidence show for Asciminib in Non-Hodgkin Lymphoma (NHL)?
Trials of Asciminib in Non-Hodgkin Lymphoma (NHL) are registered but none has completed, so there is no outcome evidence from those studies yet; the record is a signal of research interest. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target BCR. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-06. Page built 2026-10-07.